New Members Bring Extensive Clinical Diabetes
Management and FDA Expertise
Know Labs, Inc. (NYSE American: KNW), an emerging developer of
non-invasive medical diagnostic technology, today announced the
appointment of four new members to the Company’s Medical and
Scientific Advisory Board. The new additions to the Advisory Board
are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish
Garg. They bring to the board extensive experience in clinical
diabetes management, including the advancement of new technologies
and innovation in medical diagnostics.
The Medical and Scientific Advisory Board is chaired by Know
Labs’ Chief Medical Officer, Dr. James H. “Andy” Anderson. The
Advisory Board provides guidance to the executive team and Board of
Directors at Know Labs as the Company moves from the laboratory to
clinical testing and thence to the FDA for clearance of the first
truly non-invasive continuous glucose monitor.
Jeff Hitchcock is the Founder, President, and CEO of
Children with Diabetes (CWD), an Honorary Member of the
International Society for Pediatric and Adolescent Diabetes
(ISPAD), and a recipient of the T1D Exchange 2021 Outstanding
Parent Advisor Award. Hitchcock founded CWD in 1995 in response to
his then seven-year-old daughter’s T1D diagnosis in 1989. Inspired
by his family’s experience, Hitchcock set out to create an
informative online destination with resources and support for
families dealing with T1D. CWD provides families and caregivers
with guidance through original high-quality, science-based content
and practical suggestions from trusted sources including pediatric
endocrinologists, certified diabetes educators, nurses,
nutritionists, researchers, advocates, and fellow parents.
Karmeen Kulkarni, MS, RD, BC-ADM, CDCES, is a certified
diabetes care and education specialist, board certified advanced
diabetes manager and registered dietitian. Recognized
internationally for her clinical expertise and contributions to
nutrition and diabetes management, Kulkarni has received numerous
national awards from the American Dietetic Association, American
Diabetes Association and Abbott Diabetes Care. Most recently,
Kulkarni served as the Director of Global Scientific Affairs,
Continuous Glucose Monitoring (CGM), at Abbott Diabetes Care. Prior
to her time at Abbott Diabetes Care, Kulkarni coordinated the
Diabetes Center at St. Mark’s Hospital, recognized as a Regional
Center for the Intermountain West, serving adolescent to geriatric
populations and specializing in insulin pumps, multiple daily
injection (MDI) therapy, and CGMs.
Meng Tan, M.D., is currently Professor Emeritus of
Internal Medicine, Division of Metabolism, Endocrinology and
Diabetes at the University of Michigan. Dr. Tan graduated with his
M.D. from Dalhousie University, Halifax, Canada, and completed his
post-doctoral training in diabetes at the Joslin Diabetes Center,
Harvard University and in lipoprotein metabolism at the
Cardiovascular Research Institute, University of California, San
Francisco. Prior to joining the University of Michigan, he was a
Distinguished Medical Fellow, Lilly Research Laboratories and
Global Medical Director, Diabetes Endocrine Platform Team at Eli
Lilly and Company. Dr. Tan was Professor of Medicine and
Biochemistry and Head, Division of Endocrinology and Metabolism,
Dalhousie University before working in diabetes-related industry.
He also previously held several leadership roles in
diabetes-focused organizations, including serving as a past
president of the Canadian Diabetes Association and Vice President
of the International Diabetes Federation.
Satish Garg, M.D., is a Professor of Medicine and
Pediatrics at the Adult Clinic of the Barbara Davis Center for
Diabetes (BDC) at the University of Colorado School of Medicine.
Dr. Garg joined the Barbara Davis Center in 1988 and became the
Founder and Director of the BDC Adult Clinic. Dr. Garg has
published over 350 original manuscripts in peer-reviewed journals
and his research interests include the development of new
diagnostic and therapeutic tools related to clinical diabetes
management. He has been part of several studies that have brought
technological breakthroughs to diabetes care, including the FDA
approved several Continuous Glucose Monitors (CGMs) and Medtronic
MiniMed 670G and 780G hybrid closed-loop systems. Dr. Garg also
serves as the Editor-in-Chief of Diabetes Technology and
Therapeutics Journal, one of the leading journals in the field of
emerging diabetes technologies and therapeutics. He is also the
Director of the Achieve Targets in Diabetes Care (ATDC) Conference
held in July annually in Keystone, Colorado.
The new appointees will join the two existing members of the
Medical and Scientific Advisory Board, Larry Ellingson, Vice
President of the National Diabetes Volunteer Leadership Council,
who recently joined the Know Labs Board of Directors, and Donna
Ryan, RN, RD, MPH, CDE, former President of the American
Association of Diabetes Educators.
“We are very pleased to expand our existing Medical and
Scientific Advisory Board with these distinguished researchers,
innovators and clinical experts,” said Ron Erickson, CEO and
Chairman at Know Labs. “They share a deep passion for advancing
diabetes management, a central part of Know Labs’ mission. As we
work to bring the first FDA-cleared non-invasive blood glucose
monitor to the marketplace, their insights will be instrumental in
advancing our ongoing clinical research and in understanding the
specific needs of the patient populations our device is designed to
support."
For more information on Know Labs, visit www.knowlabs.co.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the
NYSE American Exchange under the stock symbol “KNW.” The Company’s
platform technology uses spectroscopy to direct electromagnetic
energy through a substance or material to capture a unique
molecular signature. The technology can be integrated into a
variety of wearable, mobile or bench-top form factors. This
patented and patent-pending technology makes it possible to
effectively identify and monitor analytes that could only
previously be performed by invasive and/or expensive and
time-consuming lab-based tests. The first application of the
technology will be in a product marketed as a non-invasive glucose
monitor. The device will provide the user with accessible and
affordable real-time information on blood glucose levels. This
product will require U.S. Food and Drug Administration clearance
prior to its introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,” “should,” “would,” “plans,” “expects,”
“anticipates,” “continue,” “estimate,” “project,” “intend,”
“likely,” “forecast,” “probable,” “potential,” and similar
expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, many of which are beyond Know
Labs, Inc.’s ability to control, and actual results may differ
materially from those projected in the forward-looking statements
as a result of various factors. These risks and uncertainties also
include such additional risk factors as are discussed in the
Company’s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended
September 30, 2022, Forms 10-Q and 8-K, and in other filings we
make with the Securities and Exchange Commission from time to time.
These documents are available on the SEC Filings section of the
Investor Relations section of our website at www.knowlabs.co. The
Company cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231214412093/en/
For Know Labs Media Inquiries: Matter Health Abby Mayo
Knowlabs@matternow.com Ph. (617) 272-0592
Know Labs, Inc.: Jordyn Hujar jordyn@knowlabs.co Ph.
(206) 629-6414
Know Labs (AMEX:KNW)
Historical Stock Chart
From Apr 2024 to May 2024
Know Labs (AMEX:KNW)
Historical Stock Chart
From May 2023 to May 2024